Success Metrics

Clinical Success Rate
95.0%

Based on 19 completed trials

Completion Rate
95%(19/20)
Active Trials
4(12%)
Results Posted
11%(2 trials)
Terminated
1(3%)

Phase Distribution

Ph phase_2
2
6%
Ph not_applicable
21
64%
Ph phase_1
4
12%
Ph early_phase_1
2
6%
Ph phase_4
1
3%

Phase Distribution

6

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution30 total trials
Early Phase 1First-in-human
2(6.7%)
Phase 1Safety & dosage
4(13.3%)
Phase 2Efficacy & side effects
2(6.7%)
Phase 4Post-market surveillance
1(3.3%)
N/ANon-phased studies
21(70.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.4%

19 of 22 finished

Non-Completion Rate

13.6%

3 ended early

Currently Active

4

trials recruiting

Total Trials

33

all time

Status Distribution
Active(5)
Completed(19)
Terminated(3)
Other(6)

Detailed Status

Completed19
unknown6
Recruiting4
Withdrawn2
Enrolling by invitation1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
33
Active
4
Success Rate
95.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (6.7%)
Phase 14 (13.3%)
Phase 22 (6.7%)
Phase 41 (3.3%)
N/A21 (70.0%)

Trials by Status

completed1958%
enrolling_by_invitation13%
recruiting412%
unknown618%
withdrawn26%
terminated13%

Recent Activity

Clinical Trials (33)

Showing 20 of 33 trialsScroll for more
NCT06194955Not Applicable

The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function

Completed
NCT07207148

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

Recruiting
NCT07398300Not Applicable

Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion

Recruiting
NCT07368855Not Applicable

GLP-1 Medicines and Mental Health Changes

Completed
NCT01851694Not Applicable

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

Recruiting
NCT07042672

Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity

Recruiting
NCT07092605Early Phase 1

Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

Enrolling By Invitation
NCT06913881

Comparative Cardiovascular Effectiveness of GLP-1 RAs vs. Insulin in Early-Onset Type 2 Diabetes

Completed
NCT04133922Early Phase 1

Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes

Withdrawn
NCT01880827Phase 1

Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery

Completed
NCT03702660Not Applicable

Effect of GIP After a Meal in Patients With Type 2 Diabetes

Completed
NCT02731664Phase 1

GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans

Completed
NCT03414333Not Applicable

To Determine the Effect of GLP1 on Cognitive Function, Brain Glucose Metabolism and Neuroplasticity.

Completed
NCT02127996Phase 2

GLP-1 Loading During Elective Percutaneous Coronary Intervention

Unknown
NCT02370745Not Applicable

Characterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal Muscle

Completed
NCT00686972Phase 2

The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition

Terminated
NCT03195257Not Applicable

Glucose-Dependent Insulinotropic Polypeptide - Effects on Markers of Bone Turnover in Patients With Type 1 Diabetes

Completed
NCT01677104Not Applicable

The Microvascular Function of GLP-1 and Its Analogues

Completed
NCT01795144Phase 1

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

Completed
NCT02650596Not Applicable

Effects of GLP-1 on Chronic Heart Failure

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
33